Another Award | Following the AI Class III Certificate for Pneumonia, Inference Medical has been highly recognized by many institutions again!
This selection is the first time that China Medical Equipment Association has included artificial intelligence-assisted diagnosis products in the selection of excellent domestic medical equipment. Through the selection evaluation standard formulation, enterprise declaration, expert defense and other processes, the relevant evaluation has been completed. In the end, there are only three enterprises in the country for auxiliary diagnosis. Product selected. As a leading enterprise in the field of auxiliary diagnosis, Inference Medical not only deeply cultivates medical treatment, but also innovates many times in clinical trials and product registration certificates, and is at the forefront in clinical application and commercial promotion. This selection not only participates as an enterprise, but also actively cooperates with the association to conduct various investigations to understand the application situation, and provides sufficient evidence and supporting materials for the association to formulate the selection process and standards. The selection of batches has laid a good foundation.
CStone's pivotal clinical trial application for lorlatinib in ROS1-positive advanced non-small cell lung cancer was approved in China
On January 4, CStone Pharmaceuticals (02616.HK), a Hong Kong-based innovative pharmaceutical company, announced that lorlatinib (formerly known as lorlatinib) has applied for a clinical trial for ROS1-positive advanced non-small cell lung cancer (NSCLC). (IND) has been approved by the China National Medical Products Administration (NMPA). This is the world's first pivotal study of lorlatinib in ROS1-positive NSCLC.
From clinical development to localized intelligent manufacturing, Weisheng Pharmaceutical's Greater China R&D and Manufacturing Base Laid the Foundation
On January 10, 2022, VISEN Pharmaceuticals, an innovative biopharmaceutical company focusing on endocrine-related therapeutics, held a groundbreaking ceremony for its R&D and manufacturing base in Greater China in Suzhou Industrial Park. This is a key step for Weisheng Pharmaceutical to actively advance the project into a substantive stage since the signing of the memorandum of cooperation with Suzhou Industrial Park in May 2021, marking the whole chain of Weisheng Pharmaceutical in the field of endocrine innovative drugs from R&D, production to sales The layout is getting better and better. With the favorable policies of the state to encourage innovative drugs and the great opportunity of the "14th Five-Year Plan" of the Yangtze River Delta, Weisheng Pharmaceutical will use this base as a new driving force to further improve the accessibility of patients to innovative endocrine drugs, so that more Chinese endocrine patients Benefit from the world's cutting-edge and reliable treatment solutions earlier, and help realize the grand blueprint of "Healthy China 2030".
New anti-inflammatory drug! AbbVie's oral JAK1 inhibitor Rinvoq applies for a new indication for the treatment of radiologically negative axial spondyloarthritis (nr-axSpA)
January 11, 2022 /Bio Valley BIOON / -- AbbVie (AbbVie) recently announced that it has submitted to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) oral JAK1 inhibitor Rinvoq ( New Indication Application for upadacitinib, upadacitinib, 15 mg once daily) for the treatment of axial spondyloarthritis with insufficient response to non-steroidal anti-inflammatory drugs (NSAIDs), objective signs of inflammation, and active radiology negative inflammation (nr-axSpA) in adult patients.
Important progress has been made in the mechanism of action of bicyclol against viral hepatitis
The research paper "Bicyclol Attenuates Liver Inflammation Induced by Infection of Hepatitis C Virus via Repressing ROS-Mediated Activation of MAPK/NF-κB Signaling Pathway" with Ph.D. student Li Hu as the first author, Jiang Jiandong and Peng Zonggen as co-corresponding authors Published in the journal Front. Pharmacol. (2018). Recommended by F1000 Prime in January 2019. The recommender is Professor Philip Rosenthal, an authoritative expert in the field of gastroenterology and hepatology at the University of California, who believes that this is a "Good for Teaching" and "Interesting Hypothesis" paper.
Scientists discover new targets for triple-negative breast cancer treatment
Most basal like breast cancer (BLBC) are triple-negative breast cancer (TNBC), which has a worse prognosis than other breast cancer subtypes due to high recurrence rate and lack of targeted therapy. Therefore, finding and exploring effective targeted therapies for BLBC has become a top priority.
AI medical care has gained attention again, Anhui Inference was invited to appear at two heavyweight innovation summits
The Digital China Construction Summit has been successfully held for four consecutive years. The theme of this year's summit in Fuzhou City, Fujian Province is "Stimulating the New Momentum of Data Elements and Starting a New Journey of Digital China". A total of more than 200 exhibitors participated in the exhibition, covering digital government, digital Industry, digital society and other aspects, attracted more than 170,000 people to visit the exhibition in five days. In the exhibition area of "Anhui Artificial Intelligence Industry Delegation - Sound Valley of China", Anhui Inference brought AI innovative products to the exhibition and shared the achievements and strengths of Inference Medical in the field of AI medical care, attracting representatives and professionals from all walks of life to visit, learn and exchange ideas. .
The Summit Forum of Lung Cancer Precision Diagnosis and Treatment Center was successfully held, and AI medical treatment entered the 2.0 era
On July 28, under the guidance of the leading group to jointly promote the development of Anhui intelligent voice industry, Anhui Information Industry Investment Holding Co., Ltd., and Anhui Inference Intelligent Technology Co., Ltd. co-organized the China Sound Valley Smart Medical Summit Forum and Lung Cancer Precision Diagnosis and Treatment Center Summit Held in Hefei. Leaders of the Anhui Provincial Government, the Provincial Department of Economic and Information Technology, the Hefei Municipal Government, and the leaders of the China Sound Valley operation unit attended the conference. The conference invited guests from many authoritative hospitals across the country, academic leaders and guests from the Department of Thoracic Surgery, the Department of Radiology, and the National Center for Respiratory Medicine. At the meeting, heated discussions were held on such hot topics as precise screening and diagnosis and treatment of lung cancer assisted by AI technology, precise treatment and surgical planning of lung cancer, and three-dimensional reconstruction of external chest with AI and its application in surgery.